London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As another day of radio silence passes, i'm conscious that this lack of news extends also to DLI. now i understand that DLI is probably regarded at best as a frivolous and expensive exercise in share dilution and, at worst, as a money pit sucking what little resources Regent may have into its gaping maw, i was until a few months ago, at least comforted by the fairly frequent news flow about partnerships, app development etc.t hey may have had little or no real substance, but at least they gave the appearance of some activity in an otherwise lifeless body. however,nothing now for months, not even anything on twitter. very, very worrying.
Morning The.Italian,
Imp afraid I never expected much from the DLI. They already lost nigh on 3mil on the DBC over 3 years and although the DLI is apart of RPG, they have still effectively lost the 3.79mil usd just by comparing the current market cap with that when the DLI take over was announced. This effectively goes to show they have no idea about investing in any pharma related product (incl longevity). As you quite rightly state the DLI was nothing more than a frivolous and expensive exercise in share dilution.
Anyway, regarding news..... It would seem the profit warning is usually given around the 15th Feb, so still 4 weeks to go. What is interesting is that back in 2021 they did give out a couple of operational updates in Jan 2021 and even included an operational update with that years profit warning, however. Given that JM/JG and the hangers on own 60% of the company, I wouldn't be surprised if they didn't consider it now as their company and PI's and now just an inconvenience.
There is certainly a good amount of news that should have been announced long before now., which I should think the A team are already aware of.
Come March, the FDA process would have been going on for 10 years.....very sad indeed for a so called blockbuster product, although its now become a ballbuster product.....lol and for added insult, JGs salary is approx. 10% of the current market cap.
I notice the DVP has been taking a real beating these last few weeks, dropping nearly 30% from the recent highs.
But even with any news (unless a US licensee has been agreed and who would be picking up the phase 3 trial costs plus at least providing a cash injection of at least 4mill usd, which I very much doubt) I'm not looking forward to yet another cash call which would need to be more than 50% of the current market cap to pay for operating costs pus phase iii trials. It was only a years ago since the last one which was nigh on 50%
What sort of salaries are getting taken from the company in relation to market cap and progress?
Look at Deep Longevity Website, https://www.deeplongevity.com/team. - A lot of mention of Regent Pacific yet we don't hear a peep about how that is developing or if it has secured some deals of sort?
In relation to main asset Fortacin we do not have any clue what's going on. No consideration for shareholders whose values have been evaporated. Really disappointing, been 10 long years of disappointments when you look at the facts.
Morning bignose and dougie. can't disagree with any of that and what a depressing read it makes.not expecting nay news necessarily now before results at end of march.at least they will have to say something at that point.fear is it won't be good news!can't see really how they can avoid some further fundraise shortly.
Dougie
As far as I remember JG was on 1.5mill USD, although he did supposedly take a 30% cut during covid which is now back in place. The 1.5 mill USD, from what I remember, was based on a calc made by POM, who is an accountant, and was based on one of the earlier year end results or annual reports. Although not explicitly given he was able to deduce that amount based on what figures were available. He also emailed JM and mentioned the figure which JM didn't deny, giving some support to the amount calculated.
The remaining salaries at the time were pocket change in comparison. Not sure how much the DLI execs are paid but they surely must surely be more than the average monkey gets in peanuts.
Blimey! 1.5 million and my investment languishes 92% down. Alq must be particularly chipper at the state of affairs!
Au contraire, Keithbfk.
While there's nothing more refreshing than a deep draught of schadenfreude, any pleasure is solely down to the smug satisfaction of seeing my predictions hold firm. Not that it requires Holmesian powers of deduction to twig Recordati's indifference to Fortacin; that the American dream, always the remotest of possibilities, has been completely scuppered by "strongly positive" (= truly appalling) Ph II results, and that NMPA submission is impacted by an extraordinary history of CMC issues, but let's not dismiss the possibility of iffy study data.
What might 2024 hold for RPG, besides the inevitable going concern warning? Pushing my neck out, let's go with an end to the pretence that there's any meaningful dialogue still to be had with the FDA, a re-tabling of the China timeline, with the definite prospect of Fosun shelving launch as the company restructures and focuses on more lucrative opportunities than offered by a run of the mill knob spray. That said, Zezheng Biotech now has two bioequivalence studies of its Fortacin generic underway, although it's hard to envisage a shoal of little fishes chasing what is a very modest market, even by Chinese standards.
On the bright side, no need to worry about RPG having to raise cash to cover a Phase III study or a continuing regulatory consultancy bill, so only a few measly millions needed to cover salaries.
Unbelievable really. Total lack of regard for the shareholder. Hidden away , releasing one enthusiastic announcement a year saying things like '' discussions taking place with licensee's'' bla bla , Well these have been some seriously long discussions.
The company should be doing webinars/ online forum where they can update shareholders and open the floor for questioning. You would think the share price performance would have forced the company into action to try and stimulate a reaction but obviously not.
Problem dougie, is the with mellon and co owning just under 60%, they really don't have to do anything more than comply with minimal market reporting (annual and half yearly and profit warnings etc).the other 40% must be pretty much entirely PIs, with no focus or power. of course, the real reason for the silence is probably simply that everything is going badly,so just keep quiet about it.if there were any positive news i see no reason not to report it, now that the last fundraise is well out of the way. anyway,they can't avoid the next results date.
Now the last fundraiser is well out of the way, they are now moving on to the next one.
I expect the Chinese submission has been made (there is no reason for it not to). The FDA process, however, is anyones guess since the amateur’s have messed it up from day one.
Have to disagree with you there, Dougie. I think the majority of discussions have been pretty damn short, and on the wild premise that there's actually been any recent BD activity, becoming a deal shorter:
"Intellectual property, market exclusivity"?- "Uh, none"
"Reliable 3rd party manufacture, with security of supply"?- "Uh, no..."
"Planning in place for the HFA phasedown"?- "Eh, what's that?"
"Potential supported by historical sales"?- "Sheepish look..."
"Post approval study data or other marketing collateral?"- "Looks out of window..."
"FDA acceptable co-primary endpoint defined and validated"?- "Mumble, mumble..."
Ironically, all over in a minute...